Bibliographic record

Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes (SOUL): a randomised, double-blind…

McGuire DK, Marso SP, Deanfield JE, Hovingh GK, Sattar N, Kahn SE, Hardt-Lindberg S, Rasmussen S, Ripa MS, Wolski K, Nissen SE…. New England Journal of Medicine 2025

Document identifier: CEI-BR-074
Series: Bibliographic record
Version: 1.0
Published: 30 Jul 2026
Last reviewed: 30 Jul 2026
Certainty: Not rated

§1Bibliographic record

§1.1Record

Authors: McGuire DK, Marso SP, Deanfield JE, Hovingh GK, Sattar N, Kahn SE, Hardt-Lindberg S, Rasmussen S, Ripa MS, Wolski K, Nissen SE, Lincoff AM
Title: Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes (SOUL): a randomised, double-blind, placebo-controlled trial
Source: New England Journal of Medicine
Year: 2025
Volume, issue, pages: 392(22):2001–2012
Digital object identifier: 10.1056/NEJMoa2501006
PubMed identifier: not held by the Institute
Record type: Journal article
Institute identifier: CEI-BR-074

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

Document	Series
Monograph: Semaglutide, oral	Compound monograph
Synthesis: Semaglutide, oral in type 2 diabetes mellitus: effect on the anchor…	Evidence synthesis
Synthesis: Semaglutide, oral in atherosclerotic cardiovascular disease and…	Evidence synthesis
Synthesis: Semaglutide, oral in type 2 diabetes mellitus: tolerability and…	Evidence synthesis
Synthesis: Semaglutide, oral in atherosclerotic cardiovascular disease and…	Evidence synthesis
Synthesis: Semaglutide, oral in type 2 diabetes mellitus: durability of effect	Evidence synthesis
6 citing documents.

§1.3Subject tags

oral-semaglutide cardiovascular SOUL

Compound Evidence Institute · CEI-BR-074 · https://compoundevidence.com/bibliography/mcguire2025/ · retrieved 30 July 2026